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Abstract
Background: Because of relatively small treatment numbers together with low adverse drug reaction (ADR)
reporting rates the timely identification of ADRs affecting children and young people is problematic. The primary
objective of this study was to assess the utility of unplanned medication discontinuation as a signal for possible
ADRs in children and young people.
Methods: Using orlistat as an exemplar, all orlistat prescriptions issued to patients up to 18 years of age together
with patient characteristics, prescription duration, co-prescribed medicines and recorded clinical (Read) codes were
identified from the Primary Care Informatics Unit database between 1st Jan 2006-30th Nov 2009. Binary logistic
regression was used to assess association between characteristics and discontinuation.
Results: During the study period, 79 patients were prescribed orlistat (81% female, median age 17 years).
Unplanned medication discontinuation rates for orlistat were 52% and 77% at 1 and 3-months. Almost 20% of
patients were co-prescribed an anti-depressant. One month unplanned medication discontinuation was significantly
lower in the least deprived group (SIMD 1–2 compared to SIMD 9–10 OR 0.09 (95% CI0.01 – 0.83)) and those
co-prescribed at least one other medication. At 3 months, discontinuation was higher in young people (≥17 yr
versus, OR 3.07 (95% CI1.03 – 9.14)). Read codes were recorded for digestive, respiratory and urinary symptoms
around the time of discontinuation for 24% of patients. Urinary retention was reported for 7.6% of patients.
Conclusions: Identification of unplanned medication discontinuation using large primary care datasets may be a
useful tool for pharmacovigilance signal generation and detection of potential ADRs in children and young people.
Keywords: Pharmacovigilance, Pharmacoepidemiology, Obesity, Child, Orlistat, Adverse drug reaction, Medical
records systems, Computerized, Young people
Background
Although adverse drug reactions (ADR) represent a
major source of morbidity and mortality in adults, the
nature and frequency of ADRs affecting children and
young people remains poorly defined. Published data
suggest that ADRs account for 1.5-2.1% of paediatric
hospital admissions and affect 2.6-9.3% of paediatric in-
patients and 1.5-11.1% of paediatric outpatients [1-10].
In the past children and young people have frequently
been excluded from clinical trials and where trials are
undertaken, they are often insufficiently powered to detect
even relatively common ADRs. This means that children
and young people are often prescribed medication with
limited information about a treatment’s ADR profile, at
doses which are not evidence based, and “off–label”; a
practice which itself is associated with increased risk of
ADRs [2].
Post marketing surveillance is an essential tool in enab-
ling the detection of potentially serious ADRs; however, to
detect an ADR with a frequency of 1:10,000, at least
30,000 individuals need to be treated with the drug for at
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least 1 case to be identified. Therefore, post-marketing
surveillance requires the monitoring of large patient co-
horts exposed to a medication to detect ADRs. Currently,
pharmacovigilance systems rely primarily on spontaneous
reporting of ADRs. However under-reporting of ADRs is a
significant issue affecting all European ADR monitoring
systems. It is widely accepted that only 10% of UK and
European healthcare professionals take part in the process
of ADR reporting and that only 6-9% of ADRs affecting
adults, which should be reported, are actually reported to
the regulatory authorities [11-15]. Despite extending spon-
taneous ADR reporting in the UK to the public, and a
wider group of healthcare professionals, public reporting
rates still remain low, and significantly lower for children
and young people than adults [16].
A growing area of medical concern and drug treat-
ment is that of obesity [17,18]. Obese adolescents tend to
be become obese adults, and it is well recognised that
obesity in adults is associated with increased morbidity
and mortality [19,20].
In the UK, orlistat, is currently the only anti-obesity
drug licensed for use in severely obese (Body Mass
Index, BMI ≥30 kg/m2) adult patients or obese patients
with comorbidities. Use in adults is associated with a
30% discontinuation within 3 months due to intolerable
ADRs [21-24]. In pediatric/adolescent clinical trials, orli-
stat use has also been associated with a high level of
ADRs (97-100%) and medication discontinuation (3.4-
30%). However the majority of these orlistat studies have
included less than 30 subjects so the ADR profile in chil-
dren and young people is poorly understood [25-27].
In the UK, the majority of children and young people
who require medical intervention for obesity, even
when assessed in secondary care, are routinely reviewed
and prescribed their medication in primary care. Pri-
mary Care electronic administrative data provide a rec-
ord of relevant clinical information, service contacts
and prescribing information and can, therefore, be used to
assess the effectiveness of medications and potentially to
generate pharmacovigilance signals. Such datasets which
have been previously used for pharmacoepidemiology t
have not been widely used for pharmacovigilance and have
the potential to offer a complementary approach to rou-
tine pharmacovigilance methodologies.
Unplanned medication discontinuation (UMD), as a sig-
nal for the identification of possible ADRs, has been previ-
ously assessed in the adult population using Primary Care
electronic administrative data. This approach is based on
the recognition of an early, unplanned discontinuation of
the prescription for a medication, possibly accompanied
by switching to alternative medication. A close agreement
has been previously reported between the UMD rate and
ADR rates reported in the literature for a variety of adult
medications [28].
The primary objective of this study was to assess the util-
ity of UMD as a signal for possible ADRs in children and
young people. Using a large Primary Care electronic admin-
istrative dataset and orlistat as an exemplar, we assessed
prescribing pattern, medicine use and the potential to gen-
erate pharmacovigilance signals for medicines prescribed
with low frequency to special populations such as children
and young people.
Methods
Data source
The Primary Care Clinical Informatics Unit (PCCIU) re-
search database is a large administrative dataset covering,
in 2006, 179 Primary Care practices across Scotland [29];
representing approximately 20% of the Scottish population
(1 million patients).
The PCCIU database, contains demographic data in-
cluding gender, date of birth and socioeconomic status
based on the practice post code (the Scottish Index of
Multiple Deprivation (SIMD) 2006 quintiles) [30]: clinical
information including diagnoses, procedures and practice
encounter data, all recorded as Read codes, and prescrib-
ing data. Read codes are a national coding system used in
primary care to code and record relevant information aris-
ing from a patient encounter in a standardised format.
Read codes permit codification of a patient’s history,
symptoms, examination findings, physical signs, diagnostic
procedures, therapeutic and administrative procedures,
drugs, appliances, occupation and social information [31].
PCCIU contains validated clinical data on a large repre-
sentative proportion of the Scottish population [30,32,33].
Study population
The study population included a closed cohort, all chil-
dren and young people aged 0–16 years of age registered
with a General Practice on the 1st January 2006. This
cohort was then followed until they reached their 19th
birthday or 30th November 2009.
Exposure
All children and young people newly prescribed orlistat
(British National Formulary code 4.5) were identified
and tracked through the study period.
For this study, a “new prescription” was defined as the
first prescription for orlistat during the study period with
no previous prescription in the preceding 3 months.
Primary outcome
The primary outcome of interest was identification of a po-
tential pharmacovigilance signal, defined as the discontinu-
ation of orlistat for at least 3 months without a subsequent
prescription. Unplanned medication discontinuations were
categorised based on duration of treatment as: <1 month,
1–3 months, 4–6 months or >6 months. Duration was
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calculated from the date of the first prescription to the date
of the last prescription. If prescriptions were ongoing at the
end of the study, the child was categorised as continuing
treatment.
Because the majority of patient records identified in the
PCCIU dataset did not contain a specific reason for drug
discontinuation, clinical symptoms, diagnoses, investiga-
tions and procedures recorded as Read codes around the
time of medication discontinuation were examined. All
Read codes occurring after starting orlistat were identified.
Potential signal associations were limited to codes re-
corded during the 3 months before and 3 months after the
last prescription. Read codes were reported and sum-
marised according to the International Classification of
Diseases (ICD)-10 top level categories.
Other covariates
All co-prescriptions were extracted from the date of the
first orlistat prescription up to 3 months after the last
orlistat prescription date and classified into their re-
spective British National Formulary (BNF) therapeutic
drug classes [33]. The number of therapeutic drug clas-
ses prescribed for each patient was then determined and
classified into 3 groups: no co-prescriptions issued, 1–4
therapeutic drug classes prescribed and >4 drug classes
prescribed.
As national guidelines recommend that the BMI be cal-
culated for the purposes of diagnosis, monitoring and ini-
tiation of pharmacological treatment, the date of the last
recorded weight and height was also noted, and if assessed
more than 1 year before start of orlistat was treated as
missing.
To allow comparison between gender and develop-
mental stages, the BMI standard deviation score (BMI
SDS) was calculated based on Cole’s LMS method [34].
Individuals with a BMI SDS between 2.5 – 3.49 were
classified as overweight to obese, those with a BMI SDS
over 3.5 classified as severely obese and those over 4 as
very severely obese.
Statistical analysis
Descriptive statistics (percentages, mean (SD), median
(IQR)) were used to report the characteristics of the co-
hort. The incidence rate for orlistat prescription was cal-
culated for 2006.
Discontinuations were summarised as percentages and
reported graphically.
To explore factors that might influence the discon-
tinuation of orlistat treatment, we compared those who
discontinued orlistat treatment at one and three months
with those continuing treatment. We used binary logis-
tic regression to calculate unadjusted odds ratios (OR)
and 95% confidence intervals (CI). The factors consid-
ered included: gender, age, socioeconomic status, co-
prescribing of antidepressants, and number of co-
prescriptions. Analysis was performed using SPSS for win-
dows 19.0 (SPSS Inc, Chicago, Illinois, USA).
Ethics and approvals
Data were anonymised and no personally identifiable in-
formation was sought. Approval for the study was granted
by the Primary Care Clinical Informatics Unit research
steering committee in accordance with their research gov-
ernance process.
Results
From the study population of 166,726 children and
young people (49% female) aged 0–16 years and regis-
tered with a participating primary care practice in Jan
2006, a cohort of 79 young people newly prescribed orli-
stat during the study period were identified. In 2006, at
cohort inception, the incidence of orlistat was 0.06/
1000/year for children aged 0–16 years.
Characteristics of the individuals prescribed orlisat
The median age at first orlistat prescription was 17 years
(IQR 16 – 18), 81% were female and 55% were from
General Practices situated in the most deprived socio-
economic areas (SIMD deciles 7–10) (Table 1). Of the
79 children and young people prescribed orlistat, only
54 (68.3%) had a BMI recorded, of which 42 (53.2%) had
a BMI measured within 1 year, and 28 (35.4%) within one
month of orlistat initiation. For the 42 individuals in
whom BMI was measured within a year of orlistat initi-
ation, the median time between BMI measurement and
the index orlistat prescription was 0.3 months (IQR 0.0 –
2.2 months). The mean BMI SDS was 3.31 (SD0.9) with
only 16 (20.3%) of all patients prescribed orlistat having a
recorded BMI SDS greater than 3.5. The demographic
characteristics of individuals prescribed orlistat is de-
scribed in Table 1.
Two thirds (65.8%) of patients were co-prescribed be-
tween 1–4 drug classes/items. The medicines most
commonly co-prescribed were antibiotics (17.4% of all
prescriptions), topical skin treatments (12.4%), analge-
sics (10.7%), oral contraceptives (9.9%), asthma medica-
tions (7.4%) and antidepressants (4.1%). Four (5%)
patients prescribed orlistat were also prescribed metfor-
min. For three of these, metformin was initiated imme-
diately following cessation of the orlistat prescription.
Orlistat discontinuation
Fifty-two percent of patients (41) discontinued orlistat
medication within 1 month of the index prescription
and 77% (61) within 3 months.
Discontinuation within 1 month was not affected by
age or gender but was significantly less likely if the pa-
tient had received any co-prescription (OR 0.12 (95% CI
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0.03 – 0.41) or was in the least deprived group (OR 0.09
(95% CI 0.01 – 0.84) (SIMD 1–2) though there was no
obvious trend by deprivation category.
Gender, co-prescription and socio-economic status,
were not significantly related to 3-month discontinu-
ation, however young people over 17 years of age were
three times more likely to discontinue their prescription
at 3-months when compared with those under 17 years
of age (OR 3.07; 95%Cl 1.03 – 9.14) (Table 2).
Read codes and possible adverse events
In total, 404 Read codes were recorded from the start of
orlistat treatment to 3 months after the last orlistat pre-
scription for 77.2% (61) of the study population. The
median number of Read codes per individual was 5; IQR
1–6 (range 0–51), and 20.3% (82) of these Read codes
related specifically to symptoms or treatments. Eight
(10.1%) patients had a Read Code recorded for: the re-
spiratory, seven (8.9%) for the genitourinary, six (7.6%)
for skin, six (7.6%) for endocrine, four (5.1%) for obstet-
ric and gynaecological, four (5.1%) for gastrointestinal,
four (5.1%) for musculoskeletal, 3 (3.8%) for mental
health and behavioural and 3 (3.8%) for the CNS sys-
tems. (Symptoms and diagnoses are listed in Table 3).
Of note 8.9% (7, all female) of all patients prescribed
orlistat had a Read code recorded within three months
of orlistat discontinuation for the genitourinary system,
of whom five were recorded as having urinary catheter-
isation and one urinary retention. None of these individ-
uals were prescribed any medication or items during the
three year study period to suggest neurological, bowel,
bladder or malignant disease, which might explain the
need for urinary catheterisation.
Discussion
We demonstrate that using UMD as a surrogate for pos-
sible adverse events, routinely collected primary care data-
sets may be used for pharmacovigilance signal generation,
although validation of generated signals and confirmation
of potential ADRs will require appropriately designed pro-
spective studies. We believe that this approach will be
complementary to the spontaneous reporting systems cur-
rently in use and enhance the capability of these systems
to widen the breadth of ADRs detected while reducing
Table 1 Patient characteristics at time of first orlistat prescription during the follow up period (1st Jan 2006 -30th Nov 2009)
Orlistat population Male Female
(N = 79) (N = 15) (N = 64)
(19% of total) (81% of total)
Age n (%)
Children (under 17 years) 24 (30.5%) 4 (26.7%) 20 (31.3%)
Young people (17 – 18 years) 55 (69.6%) 11 (73.3%) 44 (68.7%)
Median (IQR) 17 (16–18)
BMI SDS n (%)
<2.5 12 (15.2%) 0 12 (18.8%)
2.5 – 3.49 24 (30.4%) 6 (40%) 18 (28.1%)
>3.5 18 (22.8%) 6 (40%) 12 (18.8%)
Missing 25 (31.6%) 3 (20%) 22 (34.4%)
Mean (SD) 3.13 (1.0)
Deprivation SIMD (2006) n (%)
1-2 (least deprived) 8 (10.1%) 1 (6.7%) 7 (10.9%)
3-4 7 (8.9%) 2 (13.3%) 5 (7.8%)
5-6 20 (25.3%) 3 (20.0%) 17 (26.6%)
7-8 18 (22.8%) 7 (46.7%) 11 (17.2%)
9-10 (most deprived) 26 (32.9%)* 2 (13.3%) 24 (37.5%)
Co-prescribed drug classes n (%)
0 24 (30.4%) 7 (46.7%) 17 (26.6%)
1-4 52 (65.8%) 8 (53.3%) 44 (68.8%)
>4 3 (3.8%) 0 (0.0%) 3 (4.7%)
Median (IQR) 1 (0–2)
All percentage calculated from column total. *Chi squared test for trend p = 0.03.
SIMD: Scottish Index of Multiple Deprivation, IQR: Inter-quartile range, BMI SDS: Body mass index standard deviation score.
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cost and time to ADR detection. Furthermore such an ap-
proach permits assessment of prescribing appropriateness
together with real life prescribing patterns. In this study,
one in every two patients prescribed orlistat discontinued
within a month, and more than three quarters discontin-
ued within three months, of starting treatment.
For medicines such as orlistat, continued use is likely to
reflect patient acceptability and perceived effectiveness. In
this context it is likely that early discontinuation reflects
the appearance of unwanted poorly tolerated ADRs, while
later discontinuation represents a perceived lack of re-
sponse [35]. The levels of UMD in this study are similar to
those reported by Viner at al, who noted orlistat discontin-
uations of 45% at one month, 75% at 3 months and 90% at
6 months [36].
Discontinuation at three months was significantly
more frequent in the young people aged 17 years and
over, possibly reflecting the effects of emerging auton-
omy and loss of parental influence [37-39]. One month
discontinuation was significantly associated with social
class and the presence of other co-prescribed medica-
tion, with patients from the most affluent social groups
and those co-prescribed other medications less likely to
discontinue orlistat therapy. While the association be-
tween social deprivation and poor adherence is well
recognised the observation that medication discontinu-
ation was less likely in those co-prescribed other medica-
tions runs counter to the perceived wisdom that higher
levels of non-adherence are observed among adolescents
and young adults prescribed multiple medicines [40,41].
In this study orlistat was prescribed predominantly to
adolescents females, and those from the most socially
deprived areas. Although the relationship between obes-
ity and social deprivation is well recognised, this is the
first study to report a link between social deprivation
and orlistat prescribing [42-46].
Seventy percent of the cohort prescribed orlistat was co-
prescribed medications including antibiotics, topical treat-
ments for skin conditions and analgesia. Five percent of
patients were also prescribed metformin, licensed for use
in individuals aged 10 years and older for type II diabetes
mellitus, but which is being increasingly used for the treat-
ment of obesity and insulin resistance [46-51].
In the present study, one fifth of all patients (predomin-
antly female) prescribed orlistat were also prescribed anti-
depressants at some point during the study period. In the
general adolescent population antidepressants are report-
edly prescribed to 1-5/1000 individuals per year [52-54],
therefore the high level of use observed in our study sug-
gests a significantly greater prevalence of depression in the
Table 2 Crude odds ratios for 1 month and 3 month discontinuation for factors such as: gender, age, deprivation
score, prescription of anti-depressants and co-prescription of other therapeutic drug classes
Duration of treatment Duration of treatment
<1 month ≥1 month OR 95% CI <3 month ≥3 month OR 95% CI
N = 41 N = 38 N = 61 N = 18
Gender n (%)
Female 33 (80.5%) 31 (81.6%) Ref 48 (78.7%) 16 (88.9%) Ref
Male 8 (19.5%) 7 (18.4%) 1.07 0.35–3.31 13 (21.3%) 2 (11.1%) 2.17 0.44– 10.65
Age bands n (%)
Children (under 17 years) 9 (22.0%) 15 (39.5%) Ref 15 (24.6%) 9 (50.0%) Ref
Young people (17-18 years) 32 (78.0%) 23 (60.5%) 2.32 0.87–6.21 46 (75.4%) 9 (50.0%) 3.07 1.03– 9.14
Deprivation SIMD 2006 n (%)
1-2 1 (2.4%) 7 (18.4%) 0.09 0.01–0.84 5 (8.2%) 3 (16.7%) 0.23 0.03-1.41
3-4 3 (7.3%) 4 (10.5%) 0.47 0.09–2.55 6 (9.8%) 1 (0.6%) 0.78 0.07– 8.93
5-6 12 (29.3%) 8 (21.1%) 0.94 0.28–3.09 15 (24.6%) 5 (27.8%) 0.39 0.08– 1.89
7-8 9 (22.0%) 9 (23.7%) 0.63 0.19–2.11 12 (19.7%) 6 (33.3%) 0.26 0.06– 1.23
9-10 16 (39.0%) 10 (26.3%) Ref 23 (37.7%) 3 (16.7%) Ref
Antidepressants n (%)
Yes 37 (90.2%) 28 (73.7%) Ref 51 (83.6%) 14 (77.8%) Ref
No 4 (9.8%) 10 (26.3%) 0.30 0.09–1.07 10 (16.4%) 4 (22.2%) 0.69 0.19– 2.52
Co-prescriptions issued n (%)
Yes 20 (48.8%) 4 (10.5%) Ref 22 (36.1%) 2 (11.1%) Ref
No 21 (51.2%) 34 (89.5%) 0.12 0.03–0.41 39 (63.9%) 16 (88.9%) 0.22 0.05– 1.06
CI; Confidence Interval. OR; Odds Ratio.
All percentage calculated from column total. SIMD: Scottish Index of Multiple Deprivation.
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obese t population a finding consistent with studies in
both young people and adults [54-56].
Read code, describing clinical symptoms and treat-
ments, were recorded by a primary care physician for
approximately a fifth of patients around the time of
orlistat discontinuation. Respiratory, genitourinary, endo-
crine, skin, gynaecological and gastrointestinal symptoms
were reported to occur in 10%, 8.9%, 7.6%, 7.6%, 5.1% and
5.1% of patients respectively. Data from pediatric/young
person orlistat trials suggest that adverse effects, primarily
diarrhoea, affect 97-100% of individuals, leading to a dis-
continuation rate of 2% - 30% [26,27,57]. In this study a
Read code for gastrointestinal symptoms (all of which
were abdominal pain) was only recorded for 5.1% of pa-
tients. The reasons for this apparent difference between
our data and that from clinical trials may be that patients
were pre-warned about possible gastrointestinal symptoms
and therefore did not report the ADR, or that gastrointes-
tinal side effects were so common that primary care physi-
cians did not record them as a reason for discontinuation.
An unexpected finding was the number of individuals
for whom urological system Read codes, urinary catheter-
isation and urinary retention, were recorded. The reasons
for this finding are not clear. While urinary retention is
frequently associated with neurological disorders and or
constipation, assessment of co-prescribed medicines and
items for these individuals, identified only one subject pre-
scribed laxatives and none prescribed medicines or items
commonly used for the treatment of neurological, bowel,
bladder, malignant or infective conditions during the study
period. Although orlistat use has been associated with
Table 3 Actual Symptoms and diagnoses recorded as
Read codes by the treating primary care physician within
3 months of orlistat discontinuation (n = 79)
System Number of
patients (%)
Symptoms Frequency
Respiratory 8 (10.1%) Influenza 3
Acute tonsillitis 3
Acute bronchitis
and bronchiolitis
2
Asthma 1
Chest infection 1
Acute laryngitis
and tracheitis
1
Upper respiratory infection 1
Cough 1
Respiratory symptom 1
Genitourinary 7 (8.9%) Treatment via
bladder catheter
5
Retention of urine 1
Urinary tract infection (UTI) 1
Suspected UTI 2
Cystitis 1
Dermatology 6 (7.6%) Rash and other non-
specific skin eruption
1
Dermatitis 1
Skin cyst 1
Chalazion (meibomian cyst) 1
Acne vulgaris 1
Unilateral mastalgia 1
Lump in breast 1
Psoriasis and
similar disorders
1
Endocrine 6 (7.6%) Obesity 4
Acquired hypothyroidism 2
Gynaecomastia 3
Obstetrics &
Gynaecology
4 (5.1%) Menorrhagia 1
Dysmenorrhoea 1
Spontaneous abortion 1
Codes related to
spontaneous abortion
6
Polycystic ovarian syndrome 1
Gastrointestinal 4 (5.1%) Non-infective gastritis 1
Gastritis 1
Abdominal pain 3
Abdominal discomfort 1
Irritable bowel syndrome 1
Musculoskeletal 4 (5.1%) Backache 1
Pain in lumbar spine 1
1
Table 3 Actual Symptoms and diagnoses recorded as
Read codes by the treating primary care physician within
3 months of orlistat discontinuation (n = 79) (Continued)
Closed fracture
of radius
Temporomandibular
joint disorder
1
Arthralgia of knee 1
Mental health
and behavioural
3 (3.8%) Social phobias 4
Loss of confidence 1
Anxiety state 1
Depressed mood 4
At risk of deliberate
self harm
1
Central nervous
system
3 (3.8%) In-coordination 1
Tiredness 1
Migraine 1
Headache 1
Infantile autism 1
Infection 3 (3.8%) Viral infection 3
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nephrolithiasis and acute renal injury [58,59], there are
currently no data in the literature linking orlistat with
urinary retention. However as of November 2013 (current
reporting period), the Medicines and Healthcare products
Regulatory Agency, the UK government medicine regula-
tory agency, had received two “Yellow Card” reports for
urinary retention possibly associated with orlistat use [60],
raising the possibility that the association between orlistat
use and urological symptoms observed in this study may
be real. Although the approach used in this study doesn’t
allow us to attribute causality, it is reassuring to observe
that the symptoms and diagnoses recorded by primary
care physicians around the time of orlistat discontinuation,
such as influenza infection, upper respiratory infection,
headache and menstrual irregularities are in close agree-
ment with those reported for adults in the real world [61].
Current clinical guidelines make it clear that prior to
the initiation of orlistat therapy, height and weight
should be recorded. In our study, 70% of the study co-
hort had this information recorded, and of these only a
third had measurements recorded within a month of
their initial prescription. The failure to undertake appro-
priate BMI assessment prior to orlistat initiation means
that it is not possible to determine for the majority of
patients whether orlistat was prescribed appropriately,
according to the UK guidelines.
We have previously reported that electronic prescribing
databases can be used to identify UMD in adult patients,
and that such UMD rates can be used as a surrogate for
ADR/AE rates [28,35]. However, the use of UMD does not
identify the reasons for discontinuation or the nature of
possible ADRs/AEs. The UMD and ADR results we ob-
tained for orlistat are in close agreement with previously
published UMD and ADR rates obtained using more trad-
itional methods of ascertainment, indicating that UMD
obtained from routinely collected data may represent a
surrogate marker for ADR/ADE occurrence. Using this
approach together with more traditional spontaneous
reporting systems [62], may reveal potential pharmacovigi-
lance signals at an earlier stage following introduction of a
medicine and permit a more accurate assessment of ADR
incidence than is currently possible.
The use of large primary care electronic datasets en-
ables the linkage of whole population prescription in-
formation with recorded clinical symptoms, diagnoses
and encounters. As we have demonstrated, this ap-
proach permits the assessment of prescribing trends
and identification of individuals who discontinue their
medication at an early stage before clinical effective-
ness might be expected. Assessment of clinical symp-
toms and diagnosis recorded around the time of
orlistat discontinuation identified unexpected findings
which might indicate, although not prove, the occur-
rence of an ADR to the study medication.
There were several limitations to our study. It is pos-
sible that the small number of patients prescribed orli-
stat in this study may reduce the generalisability of the
orlistat specific findings; however it does not alter the
overall conclusion that the linkage of UMD with medical
Read codes identifies possible pharmacovigilance signals
of interest. Moreover, the PCCIU-R database, like most
other prescribing/dispensing databases, only reflects pri-
mary care prescribing and does not provide information
on secondary care prescribing or over the counter pur-
chase of orlistat. It is therefore possible that patients for
whom an initial prescription was issued in secondary
care or who purchased their medication OTC may have
been missed. However this is unlikely to be a major issue
in the Western world, where primary care remains the
major source of medication prescriptions. A further limi-
tation is the lack of a specific recorded reason for orlistat
discontinuation in the PCCIU-R database, and this is the
reason why all Read codes at or about the time of dis-
continuation were identified and examined.
Conclusions
Using orlistat as the exemplar, we have demonstrated that
when unplanned medication discontinuation are linked to
clinical codes for events occurring at the time of discon-
tinuation, it is possible to generate both predictable and
unpredicted pharmacovigilance signals. These findings
support the use of this approach together with traditional
pharmacovigilance methodologies to identify possible sig-
nals and plan more specific and focused pharmacovigi-
lance studies with the aim of validating suspected ADRs.
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